Omega Therapeutics announced the appointment of Joshua Reed as Chief Financial Officer, effective May 23, 2022. Roger Sawhney, M.D., Omega's Chief Financial Officer, will serve as Chief Business Officer. Mr. Reed most recently served as Chief Financial Officer of Aldeyra Therapeutics, where he was responsible for finance, business development, investor relations, compliance, human resources, and information technology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 USD | -0.94% | -14.57% | -29.90% |
05-06 | Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.90% | 117M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- OMGA Stock
- News Omega Therapeutics, Inc.
- Omega Therapeutics Announces Appoints Joshua Reed as Chief Financial Officer, Effective May 23, 2022